Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE 2 STUDY OF SINGLE-AGENT PF-03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS

NCT02299635 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02299635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02299635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE 2 STUDY OF SINGLE-AGENT PF-03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
February 3, 2015
Completion date
January 14, 2016
Enrollment
19 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast neoplasms